NPPA Caps Retail Prices Of 13 Formulations

Mumbai : The National Pharmaceutical Pricing Authority (NPPA) has fixed retail price of 13 formulations under Drugs Prices Control Order (DPCO) 2013 based on the decision of 83rd Authority Meeting dated January 27, 2021.

The formulations include rosuvastatin + aspirin capsule, telmisartan, cilnidipine and chlorthalidone tablet, rosuvastatin + clopidogrel tablet, rosuvastatin + clopidogrel tablet, mefanamic acid + paracetamol suspension (Pyremol-MF) and vildagliptin + metformin hydrochloride (SR) tablet.

The manufacturer of these formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified. The manufacturer may add goods and services tax only if they have paid actually or it is payable to the government on the retail price as prescribed by NPPA.

The retail price for a pack of these formulations shall be arrived at by the concerned manufacturer in accordance with the retail price specified as per provisions contained in paragraph 11 of the DPCO, 2013.

The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller (SDC) and dealers.

As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

The retail price fixed is applicable only to the individual manufacturer/marketer as specified i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO 2013.

In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

  • Related Posts

    Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

    Gleneagles BGS Hospital, Kengeri, Bengaluru, part of the Fortis Healthcare Network, marked World Organ Donation Day with its annual commemorative event, ‘A Legacy That Lives On.’ The event brought together…

    NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

    Punjab: The Narcotics Control Bureau (NCB) has uncovered an alleged pharmaceutical-drug diversion network operating through rural areas of Punjab. Investigators are tracing the movement of fentanyl and other drugs regulated…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

    Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

    NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

    NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

    Sun Pharma will Need HC Nod for Semaglutide Tablet Launch

    Sun Pharma will Need HC Nod for Semaglutide Tablet Launch

    Bombay HC tells Maharashtra FDA to be ‘judicious’ after Cadila challenges order to ban sale of some medicines

    Bombay HC tells Maharashtra FDA to be ‘judicious’ after Cadila challenges order to ban sale of some medicines

    ‘Erring pharma companies’: Over 1,000 cough syrup manufacturers undergo intense audits

    ‘Erring pharma companies’: Over 1,000 cough syrup manufacturers undergo intense audits

    Maharashtra FDA permanently cancels Pune-based pharma firm’s license over six contaminated medicines, GMP lapses

    Maharashtra FDA permanently cancels Pune-based pharma firm’s license over six contaminated medicines, GMP lapses